Inhaled Nitric Oxide Market Size, Share and Growth Outlook 2026: By Offering (Product and Service) (Inhaled Nitric Oxide Gas, Delivery Systems / Devices, Technical Support and Maintenance Services), By Application, By End User, Companies to 2034
The global Inhaled Nitric Oxide Market size is forecast to increase from $465.41 Million in 2026 to $671.04 Million in 2034 at a CAGR of 4.68% between 2026 and 2034.
The Inhaled Nitric Oxide market report provides detailed analysis and outlook of Inhaled Nitric Oxide segments including By Offering (Product and Service) (Inhaled Nitric Oxide Gas, Delivery Systems / Devices, Technical Support and Maintenance Services), By Application (Persistent Pulmonary Hypertension of the Newborn (PPHN), Acute Respiratory Distress Syndrome (ARDS), Chronic Obstructive Pulmonary Disease (COPD), Cardiac Surgery / Pulmonary Hypertension Post-Surgery, Other Applications), By End User (Hospitals, Pediatric and Adult Intensive Care Units, Ambulatory Surgical Centers) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Inhaled Nitric Oxide Industry Overview
Expanding Clinical Applications Driving Industry Evolution
The inhaled nitric oxide industry is undergoing a significant transformation as researchers and manufacturers expand the therapeutic scope of nitric oxide beyond its traditional role in treating Persistent Pulmonary Hypertension of the Newborn (PPHN). Historically administered at low concentrations of approximately 20 ppm to achieve selective pulmonary vasodilation, inhaled nitric oxide is now being evaluated across a broader spectrum of infectious, inflammatory, and respiratory conditions. Advances in delivery technologies, growing understanding of nitric oxide biology, and increasing investment in novel clinical applications are creating new opportunities for therapeutic innovation within critical care and pulmonary medicine.
High-Dose Nitric Oxide Strategies Creating New Treatment Pathways
A major trend reshaping the market is the investigation of high-dose intermittent nitric oxide therapies. Leading developers, including Airgas Therapeutics and Beyond Air, are supporting multicenter clinical programs evaluating exposure levels ranging from 150 ppm to 250 ppm. These studies are exploring nitric oxide’s antimicrobial and immunomodulatory properties in severe viral community-acquired pneumonia, non-tuberculous mycobacterial infections, and chronic bronchoalveolar diseases. This shift represents a substantial departure from conventional pulmonary vasodilation applications and reflects growing industry interest in leveraging nitric oxide as a direct therapeutic agent capable of influencing host immune responses and pathogen control mechanisms.
Safety Research Advancing Next-Generation Delivery Technologies
The industry is also placing greater emphasis on mitigating risks associated with nitric oxide administration. Research published by the American Physiological Society identified important biological consequences linked to nitrogen dioxide, the primary byproduct generated during inhaled nitric oxide therapy. Investigators demonstrated that chronic nitrogen dioxide exposure significantly increased extracellular ATP concentrations within lung tissues, revealing a potential mechanism associated with persistent airway inflammation and chronic cough development. These findings are encouraging manufacturers to develop enhanced filtration technologies, improved monitoring systems, and more sophisticated gas delivery platforms capable of minimizing nitrogen dioxide exposure while preserving therapeutic effectiveness. As safety standards continue to evolve, innovations in gas purification and delivery precision are expected to become increasingly important competitive differentiators.
Nitric Oxide Signaling Research Expanding Therapeutic Insights
Growing scientific understanding of nitric oxide signaling pathways is also influencing future market opportunities. Interest in vascular and neurological signaling mechanisms has increased following clinical developments involving calcitonin gene-related peptide modulation. The publication of Phase III SPACE trial data for AJOVY highlighted the importance of pathways that interact with endothelial nitric oxide synthesis and vascular regulation. Although developed for migraine prevention, the growing body of research surrounding CGRP-mediated signaling underscores the broader therapeutic relevance of nitric oxide within inflammatory, vascular, and neurological disease processes. This expanding scientific knowledge base is supporting continued exploration of nitric oxide-related therapies across multiple medical specialties and disease categories.
Inhaled Nitric Oxide Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Inhaled Nitric Oxide market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Mallinckrodt plc (Ino Therapeutics), Linde plc , Vero Biotech LLC (Genosyl), Air Liquide S.A., Beyond Air, Inc. (LungFit), Messer Group GmbH, Bellerophon Therapeutics, Inc., EKU Elektronik GmbH, Solentim Ltd. (Advanced Instruments), Auraec. The Inhaled Nitric Oxide market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Inhaled Nitric Oxide industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
Leading companies in Inhaled Nitric Oxide industry include- Mallinckrodt plc (Ino Therapeutics), Linde plc , Vero Biotech LLC (Genosyl), Air Liquide S.A., Beyond Air, Inc. (LungFit), Messer Group GmbH, Bellerophon Therapeutics, Inc., EKU Elektronik GmbH, Solentim Ltd. (Advanced Instruments), Auraec. The Inhaled Nitric Oxide market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Inhaled Nitric Oxide Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Inhaled Nitric Oxide market remains one of the strongest-performing segments in the country.
The US Inhaled Nitric Oxide Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Inhaled Nitric Oxide market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Inhaled Nitric Oxide industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Inhaled Nitric Oxide markets
Canada's strong Inhaled Nitric Oxide sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Inhaled Nitric Oxide market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Inhaled Nitric Oxide Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Inhaled Nitric Oxide market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Inhaled Nitric Oxide population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Inhaled Nitric Oxide industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Inhaled Nitric Oxide market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Inhaled Nitric Oxide sales through 2034
France Inhaled Nitric Oxide companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Inhaled Nitric Oxide Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Inhaled Nitric Oxide distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Inhaled Nitric Oxide Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Inhaled Nitric Oxide market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Inhaled Nitric Oxide industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Inhaled Nitric Oxide industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Inhaled Nitric Oxide Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Inhaled Nitric Oxide market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Inhaled Nitric Oxide market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Inhaled Nitric Oxide Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Inhaled Nitric Oxide Market Segmentation
By Offering (Product and Service)
Inhaled Nitric Oxide Gas
Delivery Systems / Devices
Technical Support and Maintenance Services
By Application
Persistent Pulmonary Hypertension of the Newborn (PPHN)
Acute Respiratory Distress Syndrome (ARDS)
Chronic Obstructive Pulmonary Disease (COPD)
Cardiac Surgery / Pulmonary Hypertension Post-Surgery
Other Applications
By End User
Hospitals
Pediatric and Adult Intensive Care Units
Ambulatory Surgical Centers
Leading Companies in Inhaled Nitric Oxide Industry (2026)
Mallinckrodt plc (Ino Therapeutics)
Linde plc
Vero Biotech LLC (Genosyl)
Air Liquide S.A.
Beyond Air, Inc. (LungFit)
Messer Group GmbH
Bellerophon Therapeutics, Inc.
EKU Elektronik GmbH
Solentim Ltd. (Advanced Instruments)
Auraec
Countries Included
The Inhaled Nitric Oxide market report provides detailed analysis and outlook of Inhaled Nitric Oxide segments including By Offering (Product and Service) (Inhaled Nitric Oxide Gas, Delivery Systems / Devices, Technical Support and Maintenance Services), By Application (Persistent Pulmonary Hypertension of the Newborn (PPHN), Acute Respiratory Distress Syndrome (ARDS), Chronic Obstructive Pulmonary Disease (COPD), Cardiac Surgery / Pulmonary Hypertension Post-Surgery, Other Applications), By End User (Hospitals, Pediatric and Adult Intensive Care Units, Ambulatory Surgical Centers) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Inhaled Nitric Oxide Industry Overview
Expanding Clinical Applications Driving Industry Evolution
The inhaled nitric oxide industry is undergoing a significant transformation as researchers and manufacturers expand the therapeutic scope of nitric oxide beyond its traditional role in treating Persistent Pulmonary Hypertension of the Newborn (PPHN). Historically administered at low concentrations of approximately 20 ppm to achieve selective pulmonary vasodilation, inhaled nitric oxide is now being evaluated across a broader spectrum of infectious, inflammatory, and respiratory conditions. Advances in delivery technologies, growing understanding of nitric oxide biology, and increasing investment in novel clinical applications are creating new opportunities for therapeutic innovation within critical care and pulmonary medicine.
High-Dose Nitric Oxide Strategies Creating New Treatment Pathways
A major trend reshaping the market is the investigation of high-dose intermittent nitric oxide therapies. Leading developers, including Airgas Therapeutics and Beyond Air, are supporting multicenter clinical programs evaluating exposure levels ranging from 150 ppm to 250 ppm. These studies are exploring nitric oxide’s antimicrobial and immunomodulatory properties in severe viral community-acquired pneumonia, non-tuberculous mycobacterial infections, and chronic bronchoalveolar diseases. This shift represents a substantial departure from conventional pulmonary vasodilation applications and reflects growing industry interest in leveraging nitric oxide as a direct therapeutic agent capable of influencing host immune responses and pathogen control mechanisms.
Safety Research Advancing Next-Generation Delivery Technologies
The industry is also placing greater emphasis on mitigating risks associated with nitric oxide administration. Research published by the American Physiological Society identified important biological consequences linked to nitrogen dioxide, the primary byproduct generated during inhaled nitric oxide therapy. Investigators demonstrated that chronic nitrogen dioxide exposure significantly increased extracellular ATP concentrations within lung tissues, revealing a potential mechanism associated with persistent airway inflammation and chronic cough development. These findings are encouraging manufacturers to develop enhanced filtration technologies, improved monitoring systems, and more sophisticated gas delivery platforms capable of minimizing nitrogen dioxide exposure while preserving therapeutic effectiveness. As safety standards continue to evolve, innovations in gas purification and delivery precision are expected to become increasingly important competitive differentiators.
Nitric Oxide Signaling Research Expanding Therapeutic Insights
Growing scientific understanding of nitric oxide signaling pathways is also influencing future market opportunities. Interest in vascular and neurological signaling mechanisms has increased following clinical developments involving calcitonin gene-related peptide modulation. The publication of Phase III SPACE trial data for AJOVY highlighted the importance of pathways that interact with endothelial nitric oxide synthesis and vascular regulation. Although developed for migraine prevention, the growing body of research surrounding CGRP-mediated signaling underscores the broader therapeutic relevance of nitric oxide within inflammatory, vascular, and neurological disease processes. This expanding scientific knowledge base is supporting continued exploration of nitric oxide-related therapies across multiple medical specialties and disease categories.
Inhaled Nitric Oxide Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Inhaled Nitric Oxide market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Mallinckrodt plc (Ino Therapeutics), Linde plc , Vero Biotech LLC (Genosyl), Air Liquide S.A., Beyond Air, Inc. (LungFit), Messer Group GmbH, Bellerophon Therapeutics, Inc., EKU Elektronik GmbH, Solentim Ltd. (Advanced Instruments), Auraec. The Inhaled Nitric Oxide market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Inhaled Nitric Oxide industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
- Growth Inhaled Nitric Oxide Market size outlook across 3 scenarios- High growth, reference, and Low growth cases
- Market Trends, Drivers, Potential Opportunities, and Challenges faced by Inhaled Nitric Oxide companies
- Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry
- Detailed SWOT Analysis of global and regional Inhaled Nitric Oxide markets
- Competitive analysis including business description, product analysis, and financial profiles
- Key country specific analysis detailing key factors shaping the short-term and long-term outlook
- Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements
Leading companies in Inhaled Nitric Oxide industry include- Mallinckrodt plc (Ino Therapeutics), Linde plc , Vero Biotech LLC (Genosyl), Air Liquide S.A., Beyond Air, Inc. (LungFit), Messer Group GmbH, Bellerophon Therapeutics, Inc., EKU Elektronik GmbH, Solentim Ltd. (Advanced Instruments), Auraec. The Inhaled Nitric Oxide market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Inhaled Nitric Oxide Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Inhaled Nitric Oxide market remains one of the strongest-performing segments in the country.
The US Inhaled Nitric Oxide Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Inhaled Nitric Oxide market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Inhaled Nitric Oxide industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Inhaled Nitric Oxide markets
Canada's strong Inhaled Nitric Oxide sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Inhaled Nitric Oxide market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Inhaled Nitric Oxide Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Inhaled Nitric Oxide market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Inhaled Nitric Oxide population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Inhaled Nitric Oxide industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Inhaled Nitric Oxide market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Inhaled Nitric Oxide sales through 2034
France Inhaled Nitric Oxide companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Inhaled Nitric Oxide Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Inhaled Nitric Oxide distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Inhaled Nitric Oxide Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Inhaled Nitric Oxide market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Inhaled Nitric Oxide industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Inhaled Nitric Oxide industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Inhaled Nitric Oxide Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Inhaled Nitric Oxide market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Inhaled Nitric Oxide market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Inhaled Nitric Oxide Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Inhaled Nitric Oxide Market Segmentation
By Offering (Product and Service)
Inhaled Nitric Oxide Gas
Delivery Systems / Devices
Technical Support and Maintenance Services
By Application
Persistent Pulmonary Hypertension of the Newborn (PPHN)
Acute Respiratory Distress Syndrome (ARDS)
Chronic Obstructive Pulmonary Disease (COPD)
Cardiac Surgery / Pulmonary Hypertension Post-Surgery
Other Applications
By End User
Hospitals
Pediatric and Adult Intensive Care Units
Ambulatory Surgical Centers
Leading Companies in Inhaled Nitric Oxide Industry (2026)
Mallinckrodt plc (Ino Therapeutics)
Linde plc
Vero Biotech LLC (Genosyl)
Air Liquide S.A.
Beyond Air, Inc. (LungFit)
Messer Group GmbH
Bellerophon Therapeutics, Inc.
EKU Elektronik GmbH
Solentim Ltd. (Advanced Instruments)
Auraec
Countries Included
- North America- US, Canada, Mexico
- Europe- Germany, France, UK, Spain, Italy, Nordics, Others
- Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others
- Latin America- Brazil, Argentina, Others
- Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
- Get Free print authentication across single, multi, and global licenses
- Free Accompanying excel spreadsheet with complete quantitative data
- Free 2-day consulting support from the lead analyst of the team that developed the report
- Gain clear understanding of current market conditions across 20 countries and plan your decisions accordingly
- Understand competitive profiles of the leading 15 companies in the Electrosurgical Generators industry
- Stay ahead of competition through a detailed analysis of recent market developments
- Make trusted decisions building on our 10-year experience in developing reports on Electrosurgical Generators industry
CHAPTER 1- EXECUTIVE SUMMARY
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Inhaled Nitric Oxide Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Inhaled Nitric Oxide Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL INHALED NITRIC OXIDE MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Inhaled Nitric Oxide Markets in 2026
3.2. Global Historic and Forecast Inhaled Nitric Oxide Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Inhaled Nitric Oxide Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Inhaled Nitric Oxide Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Inhaled Nitric Oxide Value Chain
CHAPTER 4- INHALED NITRIC OXIDE MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Inhaled Nitric Oxide Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- INHALED NITRIC OXIDE MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Offering (Product and Service)
Inhaled Nitric Oxide Gas
Delivery Systems / Devices
Technical Support and Maintenance Services
By Application
Persistent Pulmonary Hypertension of the Newborn (PPHN)
Acute Respiratory Distress Syndrome (ARDS)
Chronic Obstructive Pulmonary Disease (COPD)
Cardiac Surgery / Pulmonary Hypertension Post-Surgery
Other Applications
By End User
Hospitals
Pediatric and Adult Intensive Care Units
Ambulatory Surgical Centers
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Inhaled Nitric Oxide Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Inhaled Nitric Oxide Market Trends and Growth Opportunities to 2034
7.5. North America Inhaled Nitric Oxide Market Size Outlook by Type
7.6. North America Inhaled Nitric Oxide Market Size Outlook by Application
7.7. North America Inhaled Nitric Oxide Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Inhaled Nitric Oxide Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Inhaled Nitric Oxide Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Inhaled Nitric Oxide Companies
CHAPTER 8- EUROPE INHALED NITRIC OXIDE MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Inhaled Nitric Oxide Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Inhaled Nitric Oxide Market Trends and Growth Opportunities to 2034
8.5. Europe Inhaled Nitric Oxide Market Size Outlook by Type
8.6. Europe Inhaled Nitric Oxide Market Size Outlook by Application
8.7. Europe Inhaled Nitric Oxide Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Inhaled Nitric Oxide Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Inhaled Nitric Oxide Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Inhaled Nitric Oxide Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Inhaled Nitric Oxide Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Inhaled Nitric Oxide Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Inhaled Nitric Oxide Companies
CHAPTER 9- ASIA PACIFIC INHALED NITRIC OXIDE MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Inhaled Nitric Oxide Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Inhaled Nitric Oxide Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Inhaled Nitric Oxide Market Size Outlook by Type
9.6. Asia Pacific Inhaled Nitric Oxide Market Size Outlook by Application
9.7. Asia Pacific Inhaled Nitric Oxide Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Inhaled Nitric Oxide Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Inhaled Nitric Oxide Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Inhaled Nitric Oxide Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Inhaled Nitric Oxide Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Inhaled Nitric Oxide Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Inhaled Nitric Oxide Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA INHALED NITRIC OXIDE MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Inhaled Nitric Oxide Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Inhaled Nitric Oxide Market Trends and Growth Opportunities to 2034
10.5. South and Central America Inhaled Nitric Oxide Market Size Outlook by Type
10.6. South and Central America Inhaled Nitric Oxide Market Size Outlook by Application
10.7. South and Central America Inhaled Nitric Oxide Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Inhaled Nitric Oxide Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Inhaled Nitric Oxide Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Inhaled Nitric Oxide Companies
CHAPTER 11- MIDDLE EAST AND AFRICA INHALED NITRIC OXIDE MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Inhaled Nitric Oxide Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Inhaled Nitric Oxide Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Inhaled Nitric Oxide Market Size Outlook by Type
11.6. Middle East and Africa Inhaled Nitric Oxide Market Size Outlook by Application
11.7. Middle East and Africa Inhaled Nitric Oxide Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Inhaled Nitric Oxide Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Inhaled Nitric Oxide Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Inhaled Nitric Oxide Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Inhaled Nitric Oxide Industry
Mallinckrodt plc (Ino Therapeutics)
Linde plc
Vero Biotech LLC (Genosyl)
Air Liquide S.A.
Beyond Air, Inc. (LungFit)
Messer Group GmbH
Bellerophon Therapeutics, Inc.
EKU Elektronik GmbH
Solentim Ltd. (Advanced Instruments)
Auraec
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Inhaled Nitric Oxide Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Inhaled Nitric Oxide Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL INHALED NITRIC OXIDE MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Inhaled Nitric Oxide Markets in 2026
3.2. Global Historic and Forecast Inhaled Nitric Oxide Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Inhaled Nitric Oxide Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Inhaled Nitric Oxide Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Inhaled Nitric Oxide Value Chain
CHAPTER 4- INHALED NITRIC OXIDE MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Inhaled Nitric Oxide Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- INHALED NITRIC OXIDE MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Offering (Product and Service)
Inhaled Nitric Oxide Gas
Delivery Systems / Devices
Technical Support and Maintenance Services
By Application
Persistent Pulmonary Hypertension of the Newborn (PPHN)
Acute Respiratory Distress Syndrome (ARDS)
Chronic Obstructive Pulmonary Disease (COPD)
Cardiac Surgery / Pulmonary Hypertension Post-Surgery
Other Applications
By End User
Hospitals
Pediatric and Adult Intensive Care Units
Ambulatory Surgical Centers
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Inhaled Nitric Oxide Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Inhaled Nitric Oxide Market Trends and Growth Opportunities to 2034
7.5. North America Inhaled Nitric Oxide Market Size Outlook by Type
7.6. North America Inhaled Nitric Oxide Market Size Outlook by Application
7.7. North America Inhaled Nitric Oxide Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Inhaled Nitric Oxide Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Inhaled Nitric Oxide Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Inhaled Nitric Oxide Companies
CHAPTER 8- EUROPE INHALED NITRIC OXIDE MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Inhaled Nitric Oxide Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Inhaled Nitric Oxide Market Trends and Growth Opportunities to 2034
8.5. Europe Inhaled Nitric Oxide Market Size Outlook by Type
8.6. Europe Inhaled Nitric Oxide Market Size Outlook by Application
8.7. Europe Inhaled Nitric Oxide Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Inhaled Nitric Oxide Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Inhaled Nitric Oxide Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Inhaled Nitric Oxide Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Inhaled Nitric Oxide Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Inhaled Nitric Oxide Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Inhaled Nitric Oxide Companies
CHAPTER 9- ASIA PACIFIC INHALED NITRIC OXIDE MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Inhaled Nitric Oxide Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Inhaled Nitric Oxide Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Inhaled Nitric Oxide Market Size Outlook by Type
9.6. Asia Pacific Inhaled Nitric Oxide Market Size Outlook by Application
9.7. Asia Pacific Inhaled Nitric Oxide Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Inhaled Nitric Oxide Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Inhaled Nitric Oxide Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Inhaled Nitric Oxide Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Inhaled Nitric Oxide Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Inhaled Nitric Oxide Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Inhaled Nitric Oxide Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA INHALED NITRIC OXIDE MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Inhaled Nitric Oxide Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Inhaled Nitric Oxide Market Trends and Growth Opportunities to 2034
10.5. South and Central America Inhaled Nitric Oxide Market Size Outlook by Type
10.6. South and Central America Inhaled Nitric Oxide Market Size Outlook by Application
10.7. South and Central America Inhaled Nitric Oxide Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Inhaled Nitric Oxide Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Inhaled Nitric Oxide Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Inhaled Nitric Oxide Companies
CHAPTER 11- MIDDLE EAST AND AFRICA INHALED NITRIC OXIDE MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Inhaled Nitric Oxide Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Inhaled Nitric Oxide Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Inhaled Nitric Oxide Market Size Outlook by Type
11.6. Middle East and Africa Inhaled Nitric Oxide Market Size Outlook by Application
11.7. Middle East and Africa Inhaled Nitric Oxide Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Inhaled Nitric Oxide Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Inhaled Nitric Oxide Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Inhaled Nitric Oxide Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Inhaled Nitric Oxide Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Inhaled Nitric Oxide Industry
Mallinckrodt plc (Ino Therapeutics)
Linde plc
Vero Biotech LLC (Genosyl)
Air Liquide S.A.
Beyond Air, Inc. (LungFit)
Messer Group GmbH
Bellerophon Therapeutics, Inc.
EKU Elektronik GmbH
Solentim Ltd. (Advanced Instruments)
Auraec
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
